User talk:Beno Marija/MitO2 Kit Produktseite: Difference between revisions
Laner Verena (talk | contribs) No edit summary |
Laner Verena (talk | contribs) No edit summary |
||
Line 16: | Line 16: | ||
|year=2019-03-01 | |year=2019-03-01 | ||
|journal=Mitochondr Physiol Network | |journal=Mitochondr Physiol Network | ||
|abstract=Gnaiger E, Laner V, Passrugger M, NeuroVive Pharmaceutical AB (2019) cell permeable compound - Mito-CII-Kit. Mitochondr Physiol Network 24.03(01):1-2. Β | |abstract=Gnaiger E, Bastos A, Laner V, Passrugger M, NeuroVive Pharmaceutical AB (2019) cell permeable compound - Mito-CII-Kit. Mitochondr Physiol Network 24.03(01):1-2. Β | ||
(##) The cell permeable compound Mito-CII-Kit is the first generation of NeuroVive Pharmaceutical AB's succinate/malonate prodrugs and was developed to stimulate and inhibit Complex II of the respiratory electron transfer system in intact cells, and will expand the toolbox for evaluating the role of mitochondria in disease. Β | (##) The cell permeable compound Mito-CII-Kit is the first generation of NeuroVive Pharmaceutical AB's succinate/malonate prodrugs and was developed to stimulate and inhibit Complex II of the respiratory electron transfer system in intact cells, and will expand the toolbox for evaluating the role of mitochondria in disease. Β |
Revision as of 11:22, 22 March 2019
User talk:Beno Marija/MitO2 Kit Produktseite
Description | Cell permeable compound - Mito-CII-Kit, 2 vials; 1 vial of NV118 (25 mg) + 1 vial of NV161 (10 mg) |
---|---|
Product ID | 60200-01 |
Type | O2k |
Link | MitoPedia: Mito-CII |
Image |
Compounds
Cell permeable compounds NV118 and NV161 - Mito-CII-Kit
Cell permeable compound - Mito-CII-Kit. |
Β» Β» Versions
Oroboros (2019-03-01) Mitochondr Physiol Network
Abstract: Gnaiger E, Bastos A, Laner V, Passrugger M, NeuroVive Pharmaceutical AB (2019) cell permeable compound - Mito-CII-Kit. Mitochondr Physiol Network 24.03(01):1-2.
(##) The cell permeable compound Mito-CII-Kit is the first generation of NeuroVive Pharmaceutical AB's succinate/malonate prodrugs and was developed to stimulate and inhibit Complex II of the respiratory electron transfer system in intact cells, and will expand the toolbox for evaluating the role of mitochondria in disease.
- Β» Product: Oroboros O2k, O2k-Catalogue
β’ Keywords: Mito-CII-Kit
β’ O2k-Network Lab: AT_Innsbruck_Oroboros, NeuroVive
Compounds of Mito-CII-Kit
- The Mito-CII-Kit is composed of equal quantities of the following Compounds:
- Cell permeable compound NV118
- Description: Succinate prodrug: C10H14O8, Molecular weight 262,2g.mol-1
- Aliquots per 25 mg
- Cell permeable compound NV161
- Description: Malonate prodrug: C9H12O8, Molecular weight 248,2g.mol-1
- Aliquots per 10 mg
- Reference:
- Ehinger JK, Piel S, Ford R, Karlsson M, SjΓΆvall F, Frostner EΓ , Morota S, Taylor RW, Turnbull DM, Cornell C, Moss SJ, Metzsch C, Hansson MJ, Fliri H, ElmΓ©r E (2016) Cell-permeable succinate prodrugs bypass mitochondrial complex I deficiency. Nat Commun 7:12317. Β»Bioblast linkΒ« - Original publication introducing Mito-CII.
Expiry date of Mito-CII
- The stability of compounds in DMSO solution at room temperature is for at least 24h. The estimated stability of the compounds in DMSO at -20 would be weeks. The aliquoted 118 and 161 are stable at -20 for 6 months+. The powder is likely stable for much longer.
- CAS-Number 1592635-33-0 for NV-118
- CAS-Number 1432752-62-9 for NV-161
Labels: MiParea: Instruments;methods
HRR: O2k-Protocol
O2k-chemicals and media